|
60 Companies |
|
66 Products |
|
66 Products |
|
77 Mechanisms of Action |
|
2 Trials |
|
576 News |
|
| «123456789101112» |
- Enrollment open: Non-drug Study to Assess the Suitability of Assessment Scales in Japanese Individuals With Down Syndrome Aged 6-30 (clinicaltrials.gov) - Jun 20, 2015
P=N/A, N=40, Recruiting, Sponsor: Chugai Pharmaceutical
Not yet recruiting --> Recruiting
- Enrollment open: Can Increased Body Mass Index Prevent Adequate Ultrasound Examination for Trisomy 21 Risk Assessment? (clinicaltrials.gov) - Jun 15, 2015
P=N/A, N=200, Recruiting, Sponsor: Benha University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial primary completion date: WSRIT: Response Inhibition Training for Children With Williams Syndrome (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=20, Recruiting, Sponsor: University of Wisconsin, Milwaukee
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2015 --> Dec 2015
- Trial primary completion date: Genetic Etiology in Premature Ovarian Insufficiency (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=100, Recruiting, Sponsor: BEGUM AYDOGAN
Trial primary completion date: Aug 2015 --> Dec 2015 Trial primary completion date: Jan 2015 --> Nov 2015
- Trial completion, Enrollment change, Biopsy: Polar Body Biopsy for Preimplantation Genetic Screening (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=33, Completed, Sponsor: Weill Medical College of Cornell University
Trial primary completion date: Jan 2015 --> Nov 2015 Active, not recruiting --> Completed | N=50 --> 33
- Trial primary completion date: FPEB: A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions (clinicaltrials.gov) - Jun 11, 2015
P1, N=155, Recruiting, Sponsor: Institute for Neurodegenerative Disorders
Active, not recruiting --> Completed | N=50 --> 33 Trial primary completion date: Dec 2014 --> Dec 2015
- New trial: Decisional Capacity and Informed Consent in Fragile X Syndrome (clinicaltrials.gov) - Jun 9, 2015
P=N/A, N=200, Not yet recruiting, Sponsor: RTI International
- New trial: Macronutrient Regulation of Ghrelin and Peptide YY (clinicaltrials.gov) - Jun 6, 2015
P=N/A, N=28, Completed, Sponsor: Duke University
- New trial: Fertility Assessment in Patients With Klinefelter Syndrome (clinicaltrials.gov) - Jun 3, 2015
P=N/A, N=60, Not yet recruiting, Sponsor: University of Pittsburgh
- New trial: Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome (clinicaltrials.gov) - Jun 3, 2015
P=N/A, N=43, Recruiting, Sponsor: Mahidol University
- ||||| beloranib (ZGN-440) / Larimar Therap
Enrollment closed: bestPWS: Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome (clinicaltrials.gov) - Jun 3, 2015
P3, N=102, Active, not recruiting, Sponsor: Zafgen, Inc.
Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Active, not recruiting
- ||| Trial completion, Enrollment change: Life Quality and Health in Patients With Klinefelter Syndrome (clinicaltrials.gov) - Jun 3, 2015
P=N/A, N=452, Completed, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed | N=1350 --> 452
- ||| Trial completion, Enrollment change: Neuropsychologic, Neuroradiologic, Endocrinologic, and Genetic Aspects of Klinefelter Syndrome (clinicaltrials.gov) - Jun 3, 2015
P=N/A, N=146, Completed, Sponsor: University of Aarhus
Enrolling by invitation --> Completed | N=1350 --> 452 Active, not recruiting --> Completed | N=450 --> 146
- Enrollment open: Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes (clinicaltrials.gov) - May 28, 2015
P=N/A, N=100, Recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed | N=450 --> 146 Not yet recruiting --> Recruiting
- oxytocin / Generic mfg.
Enrollment open, Trial initiation date: Oxytocin Trial in Prader-Willi Syndrome (clinicaltrials.gov) - May 26, 2015
P1, N=24, Recruiting, Sponsor: University of Florida
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> Mar 2015
- New trial: Non-drug Study to Evaluate the Suitability of Neurocognitive Tests and Functioning Scales for the Measurement of Cognitive and Functioning Changes in Children With Down Syndrome (clinicaltrials.gov) - May 22, 2015
P=N/A, N=42, Recruiting, Sponsor: Hoffmann-La Roche
- New trial: Can Increased Body Mass Index Prevent Adequate Ultrasound Examination for Trisomy 21 Risk Assessment? (clinicaltrials.gov) - May 14, 2015
P=N/A, N=200, Not yet recruiting, Sponsor: Benha University
- Tasigna (nilotinib) / Novartis, Inhibikase
Phase classification, Combination therapy: NICOLI: Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) (clinicaltrials.gov) - May 5, 2015
P1, N=4, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> Mar 2015 Phase classification: P4 --> P1
- ||| Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Enrollment closed: ONTARGET: Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (clinicaltrials.gov) - May 4, 2015
P2, N=80, Active, not recruiting, Sponsor: Onconova Therapeutics, Inc.
Phase classification: P4 --> P1 Recruiting --> Active, not recruiting
- New trial: Non-drug Study to Assess the Suitability of Assessment Scales in Japanese Individuals With Down Syndrome Aged 6-30 (clinicaltrials.gov) - Apr 30, 2015
P=N/A, N=40, Not yet recruiting, Sponsor: Chugai Pharmaceutical
- New trial, Preclinical: DEPOSA: T21,18 and 13 Screening by Cell Free Fetal DNA in Low Risk Patients (clinicaltrials.gov) - Apr 23, 2015
P=N/A, N=1000, Not yet recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- || Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Trial primary completion date: ONTARGET: Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 19, 2015
P2, N=80, Recruiting, Sponsor: Onconova Therapeutics, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Sep 2015
- || Trial primary completion date: EXPLAIN -FragilE X Registry: An exPlorative Longitudinal Study for chAracterIzation, Treatment Pathways and patieNt-related Outcomes (clinicaltrials.gov) - Apr 19, 2015
P=N/A, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2015 --> Sep 2015 Trial primary completion date: Feb 2015 --> Dec 2015
- Norditropin (somatropin) / Novo Nordisk
Enrollment closed: Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome (clinicaltrials.gov) - Apr 15, 2015
P=N/A, N=2000, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Feb 2015 --> Dec 2015 Enrolling by invitation --> Active, not recruiting
- Enrollment change, Trial termination: Biochemical Markers and 2 and 3D Ultrasound to ID Maternal & Fetal Complications (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=350, Terminated, Sponsor: North Shore Long Island Jewish Health System
N=2000 --> 350 | Active, not recruiting --> Terminated; No safety issues. Need to rewrite protocol
- ||| Enrollment open, Trial primary completion date: RCT/DD: DIR/ Floortime™ Parent Training Intervention for the Children With Developmental Disabilities (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=64, Recruiting, Sponsor: Kingkaew Pajareya
Need to rewrite protocol Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2015 --> Mar 2017
- Trial completion, Trial primary completion date: Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome (clinicaltrials.gov) - Apr 14, 2015
P2, N=30, Completed, Sponsor: Yolanda de Diego Otero
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2015 --> Mar 2017 Active, not recruiting --> Completed | Trial primary completion date: Mar 2011 --> Apr 2015
- New trial: Sperm Production in Kleinfelter Syndrome Patients After Mesenchymal Stem Cell Injection (clinicaltrials.gov) - Apr 10, 2015
P=N/A, N=1, Completed, Sponsor: Man Clinic for Andrology, Male Infertility and Sexual Dysfunction
- Enrollment closed: Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome (clinicaltrials.gov) - Apr 8, 2015
P=N/A, N=27, Active, not recruiting, Sponsor: Children's Hospital of Philadelphia
Active, not recruiting --> Completed | Trial primary completion date: Mar 2011 --> Apr 2015 Completed --> Active, not recruiting
- Norditropin (somatropin) / Novo Nordisk
Trial completion, Enrollment change: Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome (clinicaltrials.gov) - Apr 7, 2015
P=N/A, N=46, Completed, Sponsor: Karolinska University Hospital
Completed --> Active, not recruiting Active, not recruiting --> Completed | N=75 --> 46
- ||| metadoxine extended-release (MG01CI) / Arcturus Therap
Enrollment closed: A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome (clinicaltrials.gov) - Mar 27, 2015
P2, N=60, Active, not recruiting, Sponsor: Alcobra Ltd.
Active, not recruiting --> Completed | N=75 --> 46 Recruiting --> Active, not recruiting
- | sodium valproate / Generic mfg.
Trial completion, Enrollment change: RUBIVAL: Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial (clinicaltrials.gov) - Mar 18, 2015
P2, N=41, Completed, Sponsor: University Hospital, Bordeaux
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=60 --> 41
- Trial completion: Aneuploidy Rate and Stimulation Protocol: Recombinant Follicle Stimulating Hormone (FSH) Versus Human FSH (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=80, Completed, Sponsor: Instituto Valenciano de Infertilidad, IVI VALENCIA
Active, not recruiting --> Completed | N=60 --> 41 Recruiting --> Completed
- ||||| imatinib / Generic mfg.
Enrollment closed, Trial primary completion date: Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients (clinicaltrials.gov) - Mar 9, 2015
P3, N=242, Active, not recruiting, Sponsor: Il-Yang Pharm. Co., Ltd.
Recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Feb 2015
- Metopirone (metyrapone) / HRA Pharma
Clinical: Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome (clinicaltrials.gov) - Feb 23, 2015
P=N/A, N=25, Recruiting, Sponsor: Nationwide Children's Hospital
- || trofinetide (NNZ-2566) / Neuren, Acadia Pharma
Trial primary completion date: A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome (clinicaltrials.gov) - Feb 19, 2015
P2, N=60, Recruiting, Sponsor: Neuren Pharmaceuticals Limited
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Feb 2015 Trial primary completion date: Jun 2015 --> Sep 2015
- Trial primary completion date: ESHRE-ESTEEM: The Eshre Study Into The Evaluation of Oocyte Euploidy by Microarray Analysis (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=600, Recruiting, Sponsor: European Society of Human Reproduction and Embryology
Trial primary completion date: Jun 2015 --> Sep 2015 Trial primary completion date: Nov 2014 --> Dec 2015
- ||| imatinib / Generic mfg.
Enrollment closed: ESPHALL: Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children (clinicaltrials.gov) - Feb 19, 2015
P2, N=110, Active, not recruiting, Sponsor: Rennes University Hospital
Trial primary completion date: Nov 2014 --> Dec 2015 Recruiting --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap
Trial completion, Enrollment change, Trial primary completion date: CML 0206: Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (clinicaltrials.gov) - Feb 19, 2015
P2, N=44, Completed, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=69 --> 44 | Trial primary completion date: Jul 2010 --> Jul 2014
- || trofinetide (NNZ-2566) / Neuren, Acadia Pharma
Trial primary completion date: A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome (clinicaltrials.gov) - Feb 13, 2015
P2, N=60, Recruiting, Sponsor: Neuren Pharmaceuticals Limited
Active, not recruiting --> Completed | N=69 --> 44 | Trial primary completion date: Jul 2010 --> Jul 2014 Trial primary completion date: Dec 2014 --> Jun 2015
- |||| mavoglurant (AFQ056) / Novartis
Trial completion: Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome (clinicaltrials.gov) - Feb 13, 2015
P2, N=148, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2014 --> Jun 2015 Terminated --> Completed
- Trial completion, Enrollment change, Discordant: Detection of Chromosomal Aberrations in Non-small Cell Lung Cancer (NSCLC) Using Fluorescent in Situ Hybridization (FISH) (ALK Test) (clinicaltrials.gov) - Feb 6, 2015
P=N/A, N=1, Completed, Sponsor: Applied Spectral Imaging Ltd.
Terminated --> Completed Recruiting --> Completed | N=160 --> 1
- ||||| beloranib (ZGN-440) / Larimar Therap
Enrollment change: bestPWS: Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome (clinicaltrials.gov) - Jan 30, 2015
P3, N=102, Recruiting, Sponsor: Zafgen, Inc.
Recruiting --> Completed | N=160 --> 1 N=84 --> 102
- |||| dasatinib / Generic mfg.
Trial completion: Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 30, 2015
P2, N=236, Completed, Sponsor: Bristol-Myers Squibb
N=84 --> 102 Active, not recruiting --> Completed
- diazoxide choline controlled release (DCCR) / Soleno Therap
Enrollment closed: Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome (clinicaltrials.gov) - Jan 28, 2015
P1, N=12, Active, not recruiting, Sponsor: Essentialis, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| basmisanil (RG1662) / Roche
Trial completion, Enrollment change, Trial primary completion date: A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832) (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=118, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Completed | N=170 --> 118 | Trial primary completion date: Dec 2015 --> Dec 2014
- Trial primary completion date: Assessment of Bone Density and Bone Turnover Markers in Patients With Down Syndrome and Comparison to the Ts65Dn Model (clinicaltrials.gov) - Jan 26, 2015
P=N/A, N=60, Recruiting, Sponsor: University of Arkansas
Recruiting --> Completed | N=170 --> 118 | Trial primary completion date: Dec 2015 --> Dec 2014 Trial primary completion date: Jan 2015 --> Jan 2016
- | Bosulif (bosutinib) / Pfizer
Phase classification: Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias (clinicaltrials.gov) - Jan 26, 2015
P1/2, N=63, Active, not recruiting, Sponsor: Pfizer
Trial primary completion date: Jan 2015 --> Jan 2016 Phase classification: P2 --> P1/2
- | Bosulif (bosutinib) / Pfizer
Phase classification: B1871006: Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias (clinicaltrials.gov) - Jan 22, 2015
P1/2, N=571, Active, not recruiting, Sponsor: Pfizer
Phase classification: P2 --> P1/2 Phase classification: P2 --> P1/2
- || basmisanil (RG1662) / Roche
Trial primary completion date: A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832) (clinicaltrials.gov) - Dec 25, 2014
P=N/A, N=170, Recruiting, Sponsor: Hoffmann-La Roche
Phase classification: P2 --> P1/2 Trial primary completion date: Sep 2015 --> Dec 2015